Lucidenic acid D

Lucidenic acid D is a highly oxidized triterpenoid with anti-inflammatory and antiviral activities. Lucidenic acid D attenuates lipopolysaccharide-induced release of proinflammatory cytokines and nitric oxide, reduces the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), and inhibits skin inflammation. Lucidenic acid D suppresses 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced expression of Epstein-Barr virus (EBV) early antigen and maintains the viability of Raji cells. Lucidenic acid D can be used in studies of cancer chemoprevention^[1][2][3][4]. In Vitro:Lucidenic acid D (as methyl lucidenate D) is a new highly oxidized lanostane-type triterpenoid isolated from Ganoderma lucidum gills, with its structure elucidated using spectral evidence including mass spectrometry, ¹H-NMR, and ¹³C-NMR^[1].
Lucidenic acid D inhibits Epstein-Barr virus early antigen activation in Raji cells^[2].
Lucidenic acid D (10, 50 μg/mL; 30 min) does not alter LPS-induced p38 or JNK phosphorylation in THP-1 cells^[3].
Lucidenic acid D (50 μg/mL; 4 h) does not significantly enhance LPS-induced TNFα mRNA expression in THP-1 cells^[3].
Lucidenic acid D₂ (10-1000 mol ratio/TPA; 48 h) potently inhibits EBV-EA activation in Raji cells, with an IC₅₀ of 287 mol ratio/TPA, and maintains 70% cell viability at the highest tested concentration^[4].